<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="agents compared to the single agent. Acetylcysteine was superior to" exact="ursodeoxycholic acid" post="or silibinin to reduce ALT. Ursodeoxycholic acid was superior"/>
 <result pre="the single agent. Acetylcysteine was superior to ursodeoxycholic acid or" exact="silibinin" post="to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine"/>
 <result pre="or silibinin to reduce ALT. Ursodeoxycholic acid was superior to" exact="acetylcysteine" post="or silibinin to reduce TBIL. Conclusions: Hepatoprotective agents combined"/>
 <result pre="to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine or" exact="silibinin" post="to reduce TBIL. Conclusions: Hepatoprotective agents combined with antiviral"/>
 <result pre="function. These mechanisms may be related to the ability of" exact="ursodeoxycholic acid" post="to regulate cell cycle, apoptosis and protein biosynthesis of"/>
 <result pre="and cholagogue (9). Results of long-term observational studies showed that" exact="ursodeoxycholic acid" post="can significantly reduce the development of hepatic fibrosis (8,"/>
 <result pre="with a large amount of silibinin. it is noteworthy that," exact="silibinin" post="is the main active ingredient of silymarin (14). In"/>
 <result pre="the main active ingredient of silymarin (14). In recent years," exact="silibinin" post="has been used to treat liver cirrhosis, hepatitis, liver"/>
 <result pre="of glutathione transferase and promote the detoxification of free radicals." exact="nitric oxide" post="(NO) and its metabolite can improve microcirculation, increase tissue"/>
 <result pre="not only effective to treat liver failure caused by excessive" exact="acetaminophen" post="(paracetamol), but is also useful for liver disease arising"/>
 <result pre="Using &quot;chronic hepatitis B, hepatitis B, HBV, liver fibrosis, hepatoprotective," exact="silibinin" post="(silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile acid (UDCA)&quot;,"/>
 <result pre="hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine)," exact="acetylcysteine" post="and ursodeoxycholic bile acid (UDCA)&quot;, the study retrieved papers"/>
 <result pre="plasma 200 ml qod or albumin 10 g qod +" exact="ranitidine" post="150 mg po tid + other symptomatic and supportive"/>
 <result pre="plasma 200 ml qod or albumin 10 g qod +" exact="ranitidine" post="150 mg po tid + other symptomatic and supportive"/>
 <result pre="Fabris et al. (25) 40 39 UDCA (0.6 g/d) +" exact="lactulose" post="(100-200 g/d) Lactulose (100 - 200 g/d) 3 w"/>
 <result pre="Flisiak et al. (31) 25 25 Silibinin (0.21 g/d) +" exact="misoprostol" post="(0.8 g/d) Placebo (unclear) 24 w ALT, AST, GGT,"/>
 <result pre="compared to UDCA and silibinin. The impact of UDCA and" exact="silibinin" post="on ALT levels in patients with hepatitis B were"/>
 <result pre="(WMD = -22.32; P = 0.03, 95% CI [-42.28, -2.36])," exact="silibinin" post="(WMD = -22.40; P = 0.11, 95% CI [-49.52,"/>
 <result pre="95 % confidence intervals. UDCA was superior over NAC and" exact="silibinin" post="to reduce TBIL in patients with hepatitis B. Meta-analysis"/>
 <result pre="[-4.95, -0.17]), UDCA (WMD = -3.48; 95% CI [-7.37, -0.31])," exact="silibinin" post="(WMD = -2.09; 95% CI [-8.70, 4.52]). However, the"/>
 <result pre="In 2006, Qureshi et al reported that large doses of" exact="ursodeoxycholic acid" post="reduces ALT levels in patients with hepatitis B (28)."/>
 <result pre="(28). The meta-analysis of the current study showed that acetylcysteine," exact="ursodeoxycholic acid" post="and silibinin significantly reduced ALT, and were a liver"/>
 <result pre="of the current study showed that acetylcysteine, ursodeoxycholic acid and" exact="silibinin" post="significantly reduced ALT, and were a liver function marker"/>
 <result pre="patients with hepatitis B. The reduction in ALT levels by" exact="acetylcysteine" post="was better than ursodeoxycholic acid and silibinin. This may"/>
 <result pre="The reduction in ALT levels by acetylcysteine was better than" exact="ursodeoxycholic acid" post="and silibinin. This may be related to the ability"/>
 <result pre="and silibinin. This may be related to the ability of" exact="acetylcysteine" post="to inhibit the expression of serum II-18, IFN-Î³ and"/>
 <result pre="in the patients with hepatitis B. Some studies stated that" exact="acetylcysteine" post="should be used, and that it was more beneficial"/>
 <result pre="liver disease.Clin Liver Dis.20081247334610.1016/j.cld.2008.07.00718984463 7CaoRHuXDChengHObservation on the clinical efficiency of" exact="adenosine" post="combine with ursodeoxycholic acid in the treatment of chronic"/>
 <result pre="Dis.20081247334610.1016/j.cld.2008.07.00718984463 7CaoRHuXDChengHObservation on the clinical efficiency of adenosine combine with" exact="ursodeoxycholic acid" post="in the treatment of chronic hepatitis B with severe"/>
 <result pre="Pharm Dis.2013143689 9JooSSKangHCWonTJLeeDIUrsodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and" exact="nitric oxide" post="in rat microglia.Arch Pharm Res.2003261210677314723342 10FekajEGjataAMaxhuniMThe effect of ursodeoxycholic"/>
 <result pre="nitric oxide in rat microglia.Arch Pharm Res.2003261210677314723342 10FekajEGjataAMaxhuniMThe effect of" exact="ursodeoxycholic acid" post="in liver functional restoration of patients with obstructive jaundice"/>
 <result pre="J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631 14RenBRZhaoYYXuBHWuJLChenJLiangCYResearch of silymarin extraction and" exact="silibinin" post="purification.Lishizhen Med Materia Med Res.20122336556 15FeherJLengyelG[Silymarin in the treatment"/>
 <result pre="paraquat-induced cytotoxicity.Toxicol Letters.199684171210.1016/0378-4274(95)03446-3 17HarrisonPWendonJWilliamsREvidence of increased guanylate cyclase activation by" exact="acetylcysteine" post="in fulminant hepatic failure.Hepatology.199623510677210.1053/jhep.1996.v23.pm00086211358621135 18McClainCJPriceSBarveSDevalarjaRShedlofskySAcetaminophen hepatotoxicity: An update.Curr Gastroenterol"/>
 <result pre="Gan Zang Bing Za Zhi.2008167487918647523 20XiaGThe clinical efficacy observation of" exact="acetylcysteine" post="injection on 58 cases of chronic severe hepatitis B.West"/>
 <result pre="B.West Chin Med J.2009245123940 21ShiXFGuoSHWuGWangZYRenHLiuQThe clinical curative effect observation of" exact="acetylcysteine" post="injection on 40 cases of chronic hepatitis B.J Chongqing"/>
 <result pre="Da Xue Xue Bao Yi Xue Ban.2010352171510.3969/j.issn.1672-7347.2010.02.01420197618 25FabrisPTosittiGMazzellaGZanettiARNicolinRPellizzerGet al.Effect of" exact="ursodeoxycholic acid" post="administration in patients with acute viral hepatitis: a pilot"/>
 <result pre="with acute viral hepatitis: a pilot study.Aliment Pharmacol Ther.199913911879310468700 26AnguloPBattsKPTherneauTMJorgensenRADicksonERLindorKDLong-term" exact="ursodeoxycholic acid" post="delays histological progression in primary biliary cirrhosis.Hepatology.1999293644710.1002/hep.51029030110051462 27CAORHuXDCHENGHHUANGSBAITGANHet al.Observation"/>
 <result pre="primary biliary cirrhosis.Hepatology.1999293644710.1002/hep.51029030110051462 27CAORHuXDCHENGHHUANGSBAITGANHet al.Observation on the clinical efficiency of" exact="adenosine" post="methionine combined with ursodeoxycholic acid in the treatment of"/>
 <result pre="al.Observation on the clinical efficiency of adenosine methionine combined with" exact="ursodeoxycholic acid" post="in the treatment of chronic hepatitis B with severe"/>
 <result pre="hepatitis B with severe jaundice.Chinese J Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of" exact="ursodeoxycholic acid" post="in lowering ALT in chronic liver disease.J Pak Med"/>
 <result pre="of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.J Hepatol.20115451011910.1016/j.jhep.2010.08.03021145828 30FlisiakRProkopowiczDEffect of" exact="misoprostol" post="on serum beta2-microglobulin in the course of viral hepatitis"/>
 <result pre="course of viral hepatitis B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of" exact="misoprostol" post="on the course of viral hepatitis B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect"/>
 <result pre="hepatitis B.J Cent Plains Med.20063315701 34BaoFYQiuPYAnalyzing the adjunctive therapy of" exact="silibinin" post="phospholipid complex treat chronic hepatitis B in 86 cases.Shandong"/>
 <result pre="36WangHZhaoYLXuKC[Clinical and pathological study on effects of Qianggan Capsule combined" exact="lamivudine" post="on hepatic fibrosis in patients with chronic hepatitis B].Zhongguo"/>
 <result pre="Za Zhi.200626119788017186724 37WuYYaoDKZhuL[Clinical observation on the safety and efficacy of" exact="ursodeoxycholic acid" post="and fuzheng huayu capsule in the treatment of primary"/>
 <result pre="hepatitis B and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of" exact="valsartan" post="on liver fibrosis indexes in patients with alcoholic liver"/>
</results>
